DEK::NUP214作为XPO1依赖的转录激活因子调控白血病关键基因
该研究通过多组学方法分析57例急性髓系白血病(AML)原代样本,发现t(6;9)病例对XPO1抑制剂(Selinexor和Eltanexor)呈现选择性反应,并具有FOXC1和HOX基因过表达的转录组特征。CUT&RUN实验证实DEK::NUP214直接结合FOXC1和HOXA/B簇启动子,且XPO1抑制可选择性降低这些基因表达及结合。结果提示DEK::NUP214作为XPO1依赖的转录激活因子驱动白血病,为探索XPO1抑制剂在该人群中的应用提供了依据。
要点
- t(6;9) AML病例对XPO1抑制剂Selinexor和Eltanexor显示选择性反应。
- t(6;9)病例转录组特征为FOXC1和HOX基因过表达。
- DEK::NUP214直接结合FOXC1和HOXA/B簇启动子,XPO1抑制可选择性降低其表达与结合。
核心结论
- DEK::NUP214作为XPO1依赖的转录激活因子激活关键白血病驱动基因,为在该患者群体中探索XPO1抑制剂提供了依据。
研究设计与样本
- 对57例AML原代样本进行多组学比较,包括全基因组测序、靶向测序、转录组学和>500种化合物的药物筛选。
- 采用CUT&RUN实验检测DEK::NUP214与FOXC1及HOXA/B簇启动子的直接结合。
主要发现
- t(6;9)病例对XPO1抑制剂Selinexor和Eltanexor显示选择性反应。
- t(6;9)病例具有FOXC1和HOX基因过表达的独特转录组特征。
- CUT&RUN证实DEK::NUP214直接结合FOXC1和HOXA/B簇的启动子。
- 在t(6;9)细胞中,XPO1抑制后这些基因的表达及DEK::NUP214与其调控区域的结合选择性降低。
关键数值与推荐
- t(6;9)(p22.3;q34.1)易位/DEK::NUP214融合蛋白定义了世界卫生组织分类中较年轻AML患者的一个独立疾病实体。
- transcriptomic signature characterized by overexpression of FOXC1 and HOX genes in t(6;9) cases.
临床怎么用
- 原文未据此给出临床推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
The t(6;9)(p22.3;q34.1) translocation/DEK::NUP214 fusion protein defines a distinct subgroup of younger AML patients classified as a separate disease entity by the World Health Organization. DEK is a nuclear factor with multifunctional roles, including gene regulation, while its fusion partner, NUP214, plays a pivotal role in nuclear export by interacting with transport receptors such as XPO1. However, the precise mechanism by which DEK::NUP214 drives leukemia remains unclear. A comprehensive multi-omics comparison of 57 AML primary samples (including whole genome sequencing, targeted sequencing, transcriptomics, and drug screening with >500 compounds) revealed that t(6;9) cases display a selective response to XPO1 inhibitors (Selinexor & Eltanexor) and a distinct transcriptomic signature characterized by the overexpression of FOXC1 and HOX genes that are key leukemia mediators. CUT&RUN experiments demonstrated the direct binding of DEK::NUP214 to the promoters of FOXC1 and HOXA/B clusters. Strikingly, the expression of these genes and the binding of DEK::NUP214 to their regulatory regions were selectively reduced upon XPO1 inhibition in t(6;9) cells. Altogether, these results identified a novel function of DEK::NUP214 as an XPO1-dependent transcriptional activator of key leukemia drivers and provide a rationale to explore the use of XPO1 inhibitors in this patient population.
引用
- Kaya F, Bewicke-Copley F, Miettinen JJ, et al. DEK::NUP214 acts as an XPO1-dependent transcriptional activator of essential leukemia genes. Leukemia. 2025. PMID: 40204893. doi:10.1038/s41375-025-02593-8
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。